News

CMS proposes to expand antiemetogenic coverage


 

An oral three-drug regimen of aprepitant, a 5HT3 antagonist, and dexamethasone is reasonable and necessary immediately before and within 48 hours after moderately emetogenic chemotherapy is administered to Medicare beneficiaries, the Centers for Medicare and Medicaid Services stated in a proposed decision memo.

This regimen would be covered when it is administered in that time frame with any of the following chemotherapeutic agents, administered either singularly or in combination: alemtuzumab, azacitidine, bendamustine, carboplatin, carmustine, cisplatin, clofarabine, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, doxorubicin, epirubicin, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, oxaliplatin, and streptozocin, according to the CMS.

The proposal would expand coverage of the three-drug regimen to include its use with additional chemotherapy drugs that are not currently covered, including alemtuzumab, azacitidine, bendamustine, carboplatin, clofarabine, cytarabine, daunorubicin, idarubicin, ifosfamide, irinotecan and oxaliplatin.

CMS defines moderately emetogenic chemotherapy as any anticancer agents so designated in at least two of three guidelines published by the National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), and European Society of Medical Oncology (ESMO)/Multinational Association of Supportive Care in Cancer (MASCC).

According to the CMS, 70%-80% of all patients receiving chemotherapy experience nausea and vomiting. Chemotherapy induced emesis can impair quality of life, as well as cause dehydration, malnutrition, fatigue, confusion, electrolyte imbalance, esophageal tears and aspiration pneumonia. Further, poor control of the emesis can interrupt or force withdrawal from critical chemotherapy.

"We are mindful of the relatively minimal risks of the three-drug antiemetic regimen; the severe consequences that can occur if chemotherapy is delayed or halted altogether because of emesis; and the frequency with which new anticancer chemotherapeutic agents appear. We also recognize that the available classification schemes for chemotherapy emetogenicity may evolve as evidence continues to be developed on this problem," CMS officials stated in their proposed decision memo.

They also proposed that Medicare Administrative Contractors be allowed to determine coverage for an oral three-drug antiemesis regimen of aprepitant, a 5HT3 antagonist and dexamethasone with other anticancer chemotherapeutic agents that are FDA approved and are defined as highly or moderately emetogenic in at least two of three guidelines from NCCN, ASCO, and ESMO)/MASCC.

The CMS is seeking comments on the proposal, especially in regard to whether the term “NK-1 antagonists” should be used in its coverage manual. Aprepitant is currently the sole NK-1 antagonist component of the three drug antiemetic regimen. The CMS will respond to public comments in a final decision memorandum.

Recommended Reading

Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32
MDedge Hematology and Oncology
A randomized, double-blind, placebo-controlled study of oral coenzyme Q 10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer
MDedge Hematology and Oncology
Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting
MDedge Hematology and Oncology
Nausea and vomiting in advanced cancer: the Cleveland Clinic protocol
MDedge Hematology and Oncology
Harness side effects when selecting psychotropics for cancer patients
MDedge Hematology and Oncology
End-of-life hypoactive delirium responds to antipsychotics
MDedge Hematology and Oncology
Passport to personality: Is it the patient who's 'difficult'?
MDedge Hematology and Oncology
Clinical pathways: are we there yet?
MDedge Hematology and Oncology
Data-driven changes, pathways, and physician buy-in
MDedge Hematology and Oncology
Treatment patterns in HER2-/HR-positive postmenopausal women with metastatic breast cancer initiating first-line treatment in a community oncology setting in the US
MDedge Hematology and Oncology